Marshall Wace, LLP Lian Bio Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.87 - $3.0 $31,591 - $50,682	-16,894 Reduced 7.56%	206,497 $410,000
Q2 2022 Aug 15, 2022	BUY	$2.15 - $6.01 $423,408 - $1.18 Million	196,934 Added 744.35%	223,391 $483,000
Q1 2022 May 16, 2022	SELL	$2.8 - $6.21 $354,174 - $785,509	-126,491 Reduced 82.7%	26,457 $98,000
Q4 2021 Feb 14, 2022	BUY	$6.14 - $16.2 $939,100 - $2.48 Million	152,948 New	152,948 $942,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $31.4M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.